In the Cognition Series, part 6, Henry Nasrallah, MD, Professor of Psychiatry, Neurology and Neuroscience and Scientific Director of the CURESZ Foundation, discusses pharmacological and nonpharmacological treatments for cognitive impairment in schizophrenia with Philip Harvey, PhD, Professor of Psychiatry and Psychology, and a national expert on cognition. There are currently no FDA-approved drug treatments for cognition, however, pharmaceutical companies are trying hard to develop a medication to improve cognition, using various neurotransmitter pathways. Nonpharmacological interventions include cognitive remediation, side-by side with antipsychotic medications. Second generation antipsychotics do not impair cognition. Computerized cognitive remediation stimulate the executive functions, processing speed and working memory. In the face of COVID, there has been a need for remote cognitive assessments, which have increased in number and may even be conducted at a doctor’s office.

Editor-In-Chief Bethany Yeiser, BS
Henry A. Nasrallah, MD
Karen S. Yeiser, RN
David E. Yeiser, M. Div
Louis B. Cady, MD, FAPA
Mary Beth De Bord, JD
Stephen Rush, MD

Erik Messamore, MD, PhD
Craig Chepke, MD, FAPA
Peirce Johnston, MD
James A. Hunt, JD
Jonathan M. Meyer, MD
Carol North, MD, MPE